Polar Asset Management Partners Inc. Buys Shares of 75,000 Compass Pathways PLC Sponsored ADR $CMPS

Polar Asset Management Partners Inc. purchased a new position in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 75,000 shares of the company’s stock, valued at approximately $415,000. Polar Asset Management Partners Inc. owned approximately 0.06% of Compass Pathways as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Compass Pathways by 169.0% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 424,800 shares of the company’s stock valued at $2,931,000 after buying an additional 266,908 shares during the period. BIT Capital GmbH lifted its stake in Compass Pathways by 2,963.4% during the 4th quarter. BIT Capital GmbH now owns 288,814 shares of the company’s stock worth $1,993,000 after acquiring an additional 279,386 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Compass Pathways by 49.1% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 368,828 shares of the company’s stock valued at $2,040,000 after acquiring an additional 121,491 shares during the period. Orbimed Advisors LLC purchased a new position in Compass Pathways during the 1st quarter valued at about $6,363,000. Finally, Affinity Asset Advisors LLC grew its position in Compass Pathways by 454.2% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,108,483 shares of the company’s stock valued at $6,130,000 after acquiring an additional 908,483 shares in the last quarter. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

Compass Pathways Trading Up 0.1%

CMPS opened at $11.27 on Tuesday. Compass Pathways PLC Sponsored ADR has a 12 month low of $3.92 and a 12 month high of $15.40. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -3.58 and a beta of 2.47. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.32 and a quick ratio of 3.32. The business has a fifty day moving average price of $12.52 and a 200 day moving average price of $9.06.

Compass Pathways (NASDAQ:CMPS) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.15. Sell-side analysts expect that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on CMPS shares. Raymond James Financial reiterated a “buy” rating on shares of Compass Pathways in a research note on Friday, May 22nd. Oppenheimer reissued an “outperform” rating and issued a $20.00 price objective on shares of Compass Pathways in a research note on Tuesday, July 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a report on Friday, July 17th. TD Cowen reaffirmed a “buy” rating on shares of Compass Pathways in a research note on Monday, June 1st. Finally, Compass Point set a $25.00 target price on shares of Compass Pathways in a report on Tuesday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Compass Pathways presently has a consensus rating of “Moderate Buy” and an average price target of $23.36.

Compass Pathways Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.